Kurs & Likviditet
|2022-06-08||Ordinarie utdelning ISAB 0.00 SEK|
|2021-06-22||Extra Bolagsstämma 2021|
|2021-06-09||Ordinarie utdelning ISAB 0.00 SEK|
|2020-06-12||Extra Bolagsstämma 2020|
|2020-05-13||Ordinarie utdelning ISAB 0.00 SEK|
|2019-05-10||Ordinarie utdelning ISAB 0.00 SEK|
|2018-12-13||Extra Bolagsstämma 2018|
|2018-05-24||Ordinarie utdelning ISAB 0.00 SEK|
(Stockholm, Sweden, 24 November, 2021) Inhalation Sciences AB announces that the company's Q3 Report for 2021 (in Swedish) is now available on the company's website. For more information please visit: http://inhalation.se/investors/finansiella-rapporter/
Summary of the interim report
The clinical trial of PreciseInhale is ongoing and on schedule. ISAB expects to be able to present final results and a basis for publishing data within the coming months.
This quarter the company has signed several large orders with both new and returning customers. The company had an order backlog of SEK 1,883,000 at the end of September and has since taken in orders for an additional SEK 6,255,000.
During the third quarter, there has been an easing of restrictions on both travel and meetings, and for our part this has meant that we have been able to carry out service and training visits to customers, primarily in Europe.
At the same time, we have continued our dialogues with existing and new potential customers and seen results in the form of a number of new orders. This is a positive outcome of discussions and negotiations that, in some cases, have been going on for over a year. In connection with increased sales and marketing activities, our outstanding quotes have also increased by approximately 50% compared with the same period last year.
The activities around our clinical study continue according to plan, both operationally and budgetarily. As we have previously communicated, we expect to be able to present end results and the basis for a clinical publication within the coming months. This is one of the biggest milestones in the company's history and we are very much looking forward to the completion of the ongoing work on the study.
Regarding our IR activities, we have started a new collaboration with Redeye. In addition to company analysis, Redeye will assist ISAB with an expanded investment network and information dissemination in the form of company and CEO presentations.
The coming fourth quarter will be crucial for how 2021 looks as a whole. I, together with my team at ISAB, am dedicated to ending the year well and continuing the work of building the company further and taking the right next steps in our continuing commercialization phase.
Huddinge August 26, 2021